However, doctors differ in their views on testing before prescribing ... Slamon points out that the two pathways are linked. When HER2 is amplified, “one of the pathways that consistently ...
The new diagnostic, part of Roche’s Ventana platform, has been approved in the US under the Pathway brand since October 2022. In Europe, it is called the Ventana HER2 (4B5) test – already used ...
Roche’s PATHWAY anti-HER2/neu (4B5) Rabbit Monoclonal Primary Antibody test becomes the only FDA approved companion diagnostic indicated to aid assessment of HER2 low-metastatic breast cancer ...
Although Eisai decided not to option a HER2-targeted drug under a deal with BlissBio, Angle wants to keep working with the firms to advance its CTC technology.
OS Therapies (OSTX) announced that it has scheduled a Scientific Advice Meeting in the third quarter of 2025 to discuss the Innovative ...
The PATHWAY HER2 (4B5) test has now received approval to identify a new patient population designated as "HER2-ultralow." HER2-ultralow refers to patients who have very low levels of HER2 expression, ...
Dr. Kevin Kalinsky discusses the role of targeted therapy and clinical decision-making in managing estrogen-driven, ...
Hosted on MSN2mon
Spanish researchers develop a new CAR-T therapy that hits cancer through "a dual pathway"One of them is relying on the HER2 protein, whose overexpression helps ... the team hopes to start phase I trials as soon as possible to test the therapy on patients. CAR-T therapy is an anti ...
Hosted on MSN2mon
New breast cancer drug given green light for NHS useThe National Institute for Health and Care Excellence (Nice) said the drug can be used for “treating HER2-negative locally ... option at this stage in the pathway could be a valuable alternative ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback